KEY TOPICS COVERED
Why double sterilization is gaining ground
Annex 1 places greater emphasis on demonstrable contamination control across the entire manufacturing pathway — not just in the finished product. Sterility assurance must be proven, not presumed. RTU components reduce upstream contamination risk; terminal sterilization addresses risks introduced during filling. Together, they create a stronger compliance position and a more defensible contamination control strategy. These requirements apply equally to elastomeric components used in vials, prefilled syringes, and pharmaceutical cartridges, where combiseal and plunger validation must demonstrate equivalent sterility assurance under Annex 1's contamination control strategy framework.
Steam vs gamma in a double sterilization context
Steam and gamma remain the dominant sterilization methods for elastomeric components, but the decision between them is becoming more nuanced under double sterilization. Not all components respond equally to repeated sterilization — dynamic components such as prefilled syringe plungers are particularly sensitive to cumulative irradiation, which can affect break-loose and glide forces. Starting with steam-sterilized components provides greater flexibility when terminal gamma irradiation follows later. For dynamic components such as plungers, starting with steam sterilization before terminal gamma provides the most flexibility and the lowest risk of cumulative irradiation effects on functional performance.
Validation complexity and the QbD imperative
Every sterilization pathway creates a unique validation requirement. There is no universal shortcut: steam followed by gamma, gamma followed by gamma, and varying irradiation doses all generate separate data sets. Under Annex 1's Quality by Design philosophy, sterilization strategy is a design-stage decision, not a late-stage one — and it must be evaluated alongside elastomer formulation, coatings, washing processes, and container closure integrity validation from the outset.
WHO THIS WHITE PAPER IS FOR
This report is designed for pharmaceutical and biotech professionals in regulatory affairs, quality assurance, packaging engineering, and manufacturing strategy who are evaluating or building Annex 1-compliant sterilization strategies for injectable drug products.
